FDA
-
-
-
-
-
-
-
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
-
-
-
-
-
-
-
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
-
-
-
-
-
-
-
CERo Therapeutics (CERO) Highlights Progress
-
-
-
-
-
-
-
CERo Therapeutics (CERO) Appoints Al Kucharchuk as CFO, Kristen Pierce as Chief Development Officer
-
-
-
-
-
-
-
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

